CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana

Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook Therapeutics, Inc. - KDNY

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Chinook Therapeutics, Inc. (NasdaqGS: KDNY) to Novartis AG. Under the terms of the proposed transaction, shareholders of Chinook will receive $40.00 in cash as well as contingent value rights providing for payment of up to $4.00 per share upon the achievement of certain future regulatory milestones with respect to Chinook’s lead product candidate, atrasentan, for each share of Chinook that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([e-mail]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-kdny/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230613793053/en/

The Chinook Therapeutics Stock at the time of publication of the news with a fall of -0,29 % to 37,87EUR on Nasdaq stock exchange (14. Juni 2023, 02:00 Uhr).